A Phase 3 interventional study of stannous fluoride and sodium monofluorophosphate in Dentin Sensitivity, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-25.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Dentin Sensitivity by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Dentin Sensitivity · GlaxoSmithKline.
Among the 28 studies in Dentin Sensitivity by GlaxoSmithKline, this one is the 5th largest by enrollment, is one of 12 that started in 2016, is one of 5 in phase 3, and was the 13th registered.
290 studies on the registry are indexed under Dentin Sensitivity; 48 are open to participants now.
Browse Dentin Sensitivity studies →None of the 28 studies in Dentin Sensitivity by GlaxoSmithKline is open now. The open studies under Dentin Sensitivity, anywhere →
Of the 19 Dentin Sensitivity studies recruiting now, 6 (32%) set no upper age limit and 12 (63%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 12 started in 2016.
This study's enrollment of 242 is above the median of 60 across 281 interventional studies indexed under Dentin Sensitivity.
Median enrollment 164 across the 28 interventional studies. Of the 27 that completed or were terminated, 27 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 28 studies in Dentin Sensitivity by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This single center, comparative design study will be used to investigate the efficacy of an experimental stannous fluoride containing dentifrice in relieving dentinal hypersensitivity (DH) after short term use compared with a standard fluoride dentifrice.
This will be a single center, three day, randomized, examiner blind, two treatment arm, parallel design, stratified (by maximum baseline Schiff sensitivity score of the two selected test teeth), controlled study, in participants with at least two sensitive teeth that meet all the criteria at the screening and baseline (pre-treatment) visits. DH will be assessed at baseline (pre-treatment), post-treatment and after 3 days twice daily brushing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be instructed to dose a dry toothbrush containing 0.454% w/w of stannous fluoride (1000 parts per million \[ppm\] fluoride) with a full strip (1 inch) of toothpaste. Participants will then brush each of the two selected sensitive test teeth first followed by the whole mouth thoroughly for at least 1 minute.
Drug: stannous fluoride
Participants will be instructed to dose a dry toothbrush containing 0.76% w/w sodium monofluorophosphate (1000ppm fluoride) with a full strip (1 inch) of toothpaste. Participants will then brush each of the two selected sensitive test teeth first followed by the whole mouth thoroughly for at least 1 minute.
Drug: sodium monofluorophosphate
0.454% w/w stannous fluoride containing 1100ppm of fluoride
0.76% w/w sodium monofluorophosphate containing 1000ppm fluoride
Change From Baseline in Schiff Sensitivity Score on Day 3
Schiff sensitivity score was assessed by examiner as participant's response to an evaporative (air) stimulus after the stimulation of each individual tooth. Response of participant was scored using Schiff sensitivity scale range of 0-3; 0=Participant does not respond to air stimulation; 1=Participant responds to air stimulus but does not request discontinuation of stimulus; 2=Participant responds to air stimulus and requests discontinuation or moves from stimulus; 3= Participant responds to stimulus, considers stimulus to be painful, and requests discontinuation of the stimulus. A reduction in Schiff Sensitivity score indicates improvement in sensitivity.
Time frame: Baseline, Day 3
Change From Baseline in Schiff Sensitivity Score After Single Use
Schiff sensitivity score was assessed by examiner as participant's response to an evaporative (air) stimulus after the stimulation of each individual tooth. Response of participant was scored using Schiff sensitivity scale range of 0-3; 0=Participant does not respond to air stimulation; 1=Participant responds to air stimulus but does not request discontinuation of stimulus; 2=Participant responds to air stimulus and requests discontinuation or moves from stimulus; 3= Participant responds to stimulus, considers stimulus to be painful, and requests discontinuation of the stimulus. A reduction in Schiff Sensitivity score indicates improvement in sensitivity.
Time frame: Baseline, after single use (after 5 minutes)
Change From Baseline in Tactile Threshold Immediately After Single Use and on Day 3
Tactile threshold was assessed by examiner using a constant pressure probe (Yeaple probe) which allowed application of a known force to the dentin surface from 10 g to an upper threshold of 80g in increments of 10 g. The tactile threshold is the maximum pressure applied at which participant do not report any pain or discomfort. The tactile threshold for each tooth was determined by asking the participant whether the sensation caused discomfort. The pressure setting at which the participant gave two consecutive 'yes' responses was recorded as the tactile threshold. The higher the tactile threshold, the less sensitive the tooth.
Time frame: Baseline, after single use (after 5 minutes) and on Day 3
Participants were recruited at one center in United States.
| Milestone | Experimental: Stannous Fluoride(SnF) | Control: Sodium Monofluorophosphate(SMFP) |
|---|---|---|
| Started | 121 | 121 |
| Completed | 119 | 121 |
| Not completed | 2 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal of consent | 1 | 0 |
Schiff sensitivity score was assessed by examiner as participant's response to an evaporative (air) stimulus after the stimulation of each individual tooth. Response of participant was scored using Schiff sensitivity scale range of 0-3; 0=Participant does not respond to air stimulation; 1=Participant responds to air stimulus but does not request discontinuation of stimulus; 2=Participant responds to air stimulus and requests discontinuation or moves from stimulus; 3= Participant responds to stimulus, considers stimulus to be painful, and requests discontinuation of the stimulus. A reduction in Schiff Sensitivity score indicates improvement in sensitivity.
| score on a scale | Experimental: Stannous Fluoride(SnF) | Control: Sodium Monofluorophosphate(SMFP) |
|---|---|---|
| Change From Baseline in Schiff Sensitivity Score on Day 3 | -0.82 ± 0.644 | -0.39 ± 0.426 |
Schiff sensitivity score was assessed by examiner as participant's response to an evaporative (air) stimulus after the stimulation of each individual tooth. Response of participant was scored using Schiff sensitivity scale range of 0-3; 0=Participant does not respond to air stimulation; 1=Participant responds to air stimulus but does not request discontinuation of stimulus; 2=Participant responds to air stimulus and requests discontinuation or moves from stimulus; 3= Participant responds to stimulus, considers stimulus to be painful, and requests discontinuation of the stimulus. A reduction in Schiff Sensitivity score indicates improvement in sensitivity.
| score on a scale | Experimental: Stannous Fluoride(SnF) | Standard: Sodium Monofluorophosphate(SMFP) |
|---|---|---|
| Change From Baseline in Schiff Sensitivity Score After Single Use | -0.46 ± 0.507 | -0.45 ± 0.465 |
Tactile threshold was assessed by examiner using a constant pressure probe (Yeaple probe) which allowed application of a known force to the dentin surface from 10 g to an upper threshold of 80g in increments of 10 g. The tactile threshold is the maximum pressure applied at which participant do not report any pain or discomfort. The tactile threshold for each tooth was determined by asking the participant whether the sensation caused discomfort. The pressure setting at which the participant gave two consecutive 'yes' responses was recorded as the tactile threshold. The higher the tactile threshold, the less sensitive the tooth.
| g | Experimental: Stannous Fluoride(SnF) | Standard: Sodium Monofluorophosphate(SMFP) |
|---|---|---|
| Change from baseline post treatment | 4.01 ± 7.545 | 3.60 ± 7.252 |
| Change from baseline on Day 3 | 15.25 ± 17.766 | 3.88 ± 6.785 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Experimental: Stannous Fluoride(SnF) | 0/121 (0%) | 0/121 (0%) | 1/121 (0.8%) |
| Standard: Sodium Monofluorophosphate(SMFP) | 0/121 (0%) | 0/121 (0%) | 2/121 (1.7%) |
| Event | Experimental: Stannous Fluoride(SnF) | Standard: Sodium Monofluorophosphate(SMFP) |
|---|---|---|
| Oral Mucosal ExfoliationGastrointestinal disorders | 1/121 | 0/121 |
| Leukoplakia OralGastrointestinal disorders | 0/121 | 1/121 |
| Lip UlcerationGastrointestinal disorders | 0/121 | 1/121 |
| Age, Continuous(Years) | Experimental: Stannous Fluoride(SnF) | Control: Sodium Monofluorophosphate(SMFP) | Total |
|---|---|---|---|
| Mean | 38.0 ± 11.32 | 37.4 ± 11.01 | 37.7 ± 11.15 |
| Sex: Female, Male(Participants) | Experimental: Stannous Fluoride(SnF) | Control: Sodium Monofluorophosphate(SMFP) | Total |
|---|---|---|---|
| Female | 76 | 78 | 154 |
| Male | 45 | 43 | 88 |
| Ethnicity (NIH/OMB)(Participants) | Experimental: Stannous Fluoride(SnF) | Control: Sodium Monofluorophosphate(SMFP) | Total |
|---|---|---|---|
| Hispanic or Latino | 27 | 19 | 46 |
| Not Hispanic or Latino | 94 | 102 | 196 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Experimental: Stannous Fluoride(SnF) | Control: Sodium Monofluorophosphate(SMFP) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 9 | 10 | 19 |
| Native Hawaiian or Other Pacific Islander | 4 | 3 | 7 |
| Black or African American | 25 | 27 | 52 |
| White | 74 | 72 | 146 |
| More than one race | 8 | 8 | 16 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Shiff Sensitivity Score at Baseline(score on a scale) | Experimental: Stannous Fluoride(SnF) | Control: Sodium Monofluorophosphate(SMFP) | Total |
|---|---|---|---|
| Mean | 2.53 ± 0.389 | 2.55 ± 0.397 | 2.54 ± 0.392 |
| Tactile Threshold at Baseline(gram (g)) | Experimental: Stannous Fluoride(SnF) | Control: Sodium Monofluorophosphate(SMFP) | Total |
|---|---|---|---|
| Mean | 10.00 ± 0.000 | 10.00 ± 0.000 | 10.00 ± 0.000 |
The record gives a start of Mar 2016, a primary completion of May 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2017, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tin Fluorides